of opinion over what was an 'ideal hospital'. A speaker from the floor contributed the point that problems over this in the USA had led to the recognition of the need for a more balanced national standard which in turn had led to greater central government interventions. Mr Powell stressed again the need for responsible channels of authority at regional level, and said that the auguries for this are not good at a time when we are becoming more and more of a unitary state with local government shrivelling. He went on to speak feelingly of the current 'almost mortal hostility' between central and local government.
Dr Dunwoodie reverted to the need to alter NHS structure to take note of the problems it is currently facingan aging population, more and more hi-tech possibilities, and the difficulty of persuading people to work in unpopular parts ofthe Service. An opaque question from the floor suggested that the NHS should give 'priority to life', but Professor Abel-Smith managed to deflect this irrelevancy into the topic of quality of life; he stressed again the inevitability of considering priorities and the lack of simplistic answers to this problem.
Mr Powell said that decisions on such matters were, in practice, often taken by individuals. When he had been Minister of Health he had, on one occasion, personally committed £4 million ofthe health budget to the area ofmental abnormality. He had neverregretted this decision: he had felt a special responsibility to the mentally handicapped because they had absolutely no political influence for themselves.
The question offunds in themselves was raised, and it was reiterated that there must always be limits to spending, however generous the budget. Professor Abel-Smith did say, however, than an extra 1% of spending on the NHS would bring us into line with other comparable countries and make a substantial difference to the service.
In conclusion, it was agreed by all on the platform that the originators ofthe NHS had been quite wrong in their assumption that the cost and shape of the service could be determined by the demands made upon it; if anything, the causality works the other way round. Any Health Service is autonomous; it is not, for instance, affected by an increase or decrease in road traffic accidents. If it were, then the Minister for Transport might reasonably ask for a grant from the Health budget to improve the roads! In summing up, the Chairman, Ian Kennedy (Professor of Medical Law and Ethics, Kings College London) said that there was some inevitable pessimism in reviewing what might have been done and what has not been. We are left, he said, with the sense that our society in general has not yet understood the task that confronts it in running an efficient Health Service in the present day.
Gillian Tindall Richard Lansdown
Report of meeting of Forum on Lipids in Clinical Medicine, 19 May 1987 Lipids and thrombosis Keywords: lipids; lipoproteins; platelets; atherosclerosis; coagulation The aim ofthis meeting was to consider the effects that lipids, either in the plasma or within cells, may have on thrombotic episodes which, in turn, may play a part in the development of atherosclerosis and in later pathological events leading to myocardial infarction.
We were particularly fortunate to have Professor Russell Ross to open the session, when he outlined current thinking on the development of atherosclerosis. In his studies of non-human primates with hyperlipidaemia induced by dietary manipulation, atherosclerotic plaques were found to be essentially the same as human plaques in terms oftheir cellular content. This could be demonstrated by use of specific monoclonal antibodies. Within 7 days of introducing the diet it was possible to identify clusters of monocytes and lymphocytes throughout the arterial tree. These cells appear to be chemokinetically activated by the artery wall and were observed, under the electron microscope, penetrating the endothelium. These cells provide the early foam cells whereas accumulation of lipid by smooth muscle cells does not occur until 2 months after introduction of the diet. By this time mural thrombi were also detectable and preceded the marked proliferative response of the arterial intima. Macrophages may themselves activate blood platelets by production of thrombin on their surfaces.
The question was posedwhat is responsible for the proliferation? It appears that most of the cells involved are capable of producing growth factors. Platelets secrete platelet-derived growth factor (PDGF) (a heterodimer of the A and B chains of this protein), epidermal growth factor and also transforming growth factor. Activated macrophages secrete a disproportion of the B homodimers of PDGF. Endothelial cells and smooth muscle cells (at least in the newborn) produce forms of PDGF. Macrophages express the gene for several other growth factors.
Professor Ross concluded that it was necessary to formulate a modified form of the response-to-injury hypothesis for the development of atherosclerosis. This should explain the putative role of these growth factors in the genesis of advanced smooth muscle proliferative lesions of atherosclerosis. Dr S Moncada from the Wellcome Laboratories (UK) described properties of endothelium which have a particular relevance to the behaviour of the artery wall in thrombotic episodes, notably the release of the substances which are capable of inducing the relaxation of smooth muscle and of inhibiting platelet function. This is achieved by the synthesis in the endothelium of both prostacyclin and endotheliumderived relaxation factor (EDRF). 0141-0768/88/ 050299-03/$02.00/0 © 1988 The Royal Society of Medicine Prostacyclin has many actions including stimulation of platelet and smooth muscle adenylate cyclase, enhancement offibrinolysis, stimulation ofcholesterol metabolism and the suppression of the release from platelets of growth factors which promote smooth muscle proliferation. It is the action of prostacyclin as a platelet inhibitor and as a smooth muscle relaxant for which it has attracted attention as a metabolite of arachidonic acid.
The production of EDRF is stimulated by acetylcholine, bradykinin and other agents in intact endothelium. Its half life is less than 5 s and it acts as a relaxant by stimulation of smooth muscle guanylate cyclase. It also inhibits platelet aggregation by a similar mechanism. This activity is destroyed by superoxide radicals or Fe2+, but its breakdown is inhibited by superoxide dismutase and Cu2+.
There has been much speculation about the nature of EDRF, but Dr Moncada presented some convincing evidence that it may be nitric oxide gas. It has been known for years that nitro-compounds are potent vasodilators and are capable of generating nitric oxide. The mechanism by which nitric oxide could be generated by the endothelium is uncertain and this will certainly provide an active area for research.
The importance of lipoproteins in thrombosis provided the basis for presentations by at least three speakers. Dr K Mitropoulos (Northwick Park, London) discussed the background to his work, the prospective Northwick Park Heart Study which indicated that high levels of factor VII coagulant activity (VII C) may be associated with the later development of ischaemic heart disease. There may also be a relationship between VII C and elevated plasma lipoprotein concentrations. In his experimental work he used cholesterol-fed rabbits as a model. The diet increased the plasma concentration of VII C in its activated form (alpha VIla) and those of factor X and prothrombin. A greater synthesis of factor X and prothrombin and generation of thrombin was due to the higher ratio of alpha VIla1VII. Dietary lipid causes an increase in the concentrations of the larger triglyceride-rich lipoprotein fractions, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) which trigger a high flux within the intrinsic pathway of blood coagulation.
Dr T Barrowcliffe of the National Institute of Biological Standards (London) also stressed the importance of mural thrombi containing fibrin in the development of atherosclerosis and in the occlusion of blood vessels. In addition to an increased concentration of clotting factors, the appearance of pro-coagulant phospholipid surfaces may be of importance. These surfaces accelerate the enzymesubstrate reactions which facilitate the formation of thrombin and then fibrin. In injured vessels this surface is provided by platelet membranes, but other mechanisms may be of significance even without injury. Native lipoproteins are inactive in promoting coagulation even though they contain phospholipids on their surfaces. Free radical damage to their polyunsaturated fatty acids (including those in the phospholipid fraction) renders lipoproteins potent stimulators of thrombin formation in the absence of platelets. This effect was demonstrable by addition of peroxides of arachidonic acid to plasma. If the lipoproteins were removed from the plasma beforehand the peroxides were without effect. The most potent lipoprotein fraction was VLDL, their action emanating from the surface phospholipids. This pro-coagulant activity was enhanced by another property ofthe lipid peroxides which could inhibit antithrombin III. The possible role of free radicals and peroxide formation is currently a very active area of atherosclerosis research.
Dr K R Bruckdorfer (Royal Free Hospital School of Medicine, London) went on to discuss the role of platelets in the formation ofthrombi and the evidence that lipoproteins may affect their activity. Low density lipoprotein (LDL) was shown to increase the sensitivity of human platelets to other agonists, particularly adrenaline and adenosine diphosphate, in platelet-rich plasma using standard aggregation tests. LDL can act directly as a platelet agonist if isolated platelets are used. Furthermore LDL reverses the inhibition of platelet reactivity by prostacyclin. High density lipoprotein (HDL) has a lesser effect on platelets, except the minor subfraction which is rich in the protein apo-E and is inhibitory. Platelets appear to have a specific receptor for LDL which is different in a number of respects from the classical Brown & Golstein receptor for LDL found on fibroblasts. The platelet receptor is still present in patients with homozygous familial hypercholesterolaemia.
The effects of LDL on EDRF was studied in organ baths with rabbit aortic rings. LDL inhibited the relaxation of these rings which is caused by EDRF produced by the endothelium. LDL at high concentrations therefore has the potential to have important effects on two key issues which play a role in vasodilation and constriction. Oxidation of LDL may play a role in this.
Professor G V R Born (King's College, London) introduced his recent studies on the differences between normal and atherosclerotic vessels on the flux of labelled lipoproteins through the endothelium. He showed that the effects of shear due to haemodynamic stress induced fissures in atherosclerotic plaques. This could be demonstrated experimentally by the application of mechanical stress to normal and atherosclerotic arteries. These effects were discussed in relation to the generation of thrombi.
Dr J Betteridge (University College, London) gave a clinician's view of the effects of lipids on thrombosis. He considered the high mortality from cardiovascular diseases of patients with familial hypercholesterolaemia and with diabetes. There have, for example, been reports of increased formation of lipid peroxides in diabetes. His own work on platelets show that in both groups of patients increased malondialdehyde formation indicated a greater activity ofthe cyclooxygenase pathway leading to the formation of thromboxanes and other potent products. The increased secretion of platelet-specific proteins such as beta-thromboglobulin and PDGF could be detected in these patients.
Dr Betteridge commented that human platelets contain adrenaline and noradrenaline which are released when the cells are stimulated and there appears to be a greater release of these active materials in patients with familial hypercholesterolaemia and diabetes.
Dr T A B Sanders of King's College (London) examined the clinical use of a fish oil concentrate, Maxepa, to control thrombosis. Fish oils contain the fatty acids eicosapentaenoic (EPA) and docosahexaenoic acid (DPA) which have wide ranging pharmacological effects which include anti-inflammatory and lipid-lowering properties. High levels of consumption of these fatty acids leads to a replacement of arachidonic acid in the membrane phospholipids of diverse cell types and a modulation ofthe production of eicosanoids including prostaglandins, prostacyclins, thromboxanes and leukotrienes. Earlier work had suggested potent effects of these fatty acids on platelets in vitro. However consumption of these fatty acids had more modest effects on platelets, but they may still be of value in the treatment ofthrombogenic disorders.
Maxepa in doses of 10-15 g per day is particularly effective in lowering plasma triglyceride concentrations. At this intake, plasma cholesterol concentrations are not changed significantly. However, the potent triglyceride lowering properties may be of considerable significance when treating conditions wherecardiovascular disease is exacerbated by high concentrations of the triglyceride-rich lipoproteins (VLDL and IDL).
The meeting was well attended indicating the growing interest in this area of research. It is clear that much more can be learned about the interactions of lipids with soluble coagulation factors, platelets and the endothelium. (Accepted 27 November 1987) Report of meeting of Section of Measurement in Medicine, 14-15 September 1987 Bile acids in health and disease: update on cholesterol gallstones and bile acid diarrhoea Keywords: bile acids; diarrhoea; cholesterol gallstones; SeHCAT test; malabsorption A glittering array of international experts was assembled to consider the present state of the art in the field of bile acids.
K R Bruckdorfer Editorial Representative Forum on Lipids in Clinical Medicine
Professor Alan Hofmann delivered the first contribution, the Burroughs Wellcome Lecture on the cholehepatic and enterohepatic circulations of bile acids. The theme of a postulated circulation of bile acids from the bile ducts directly back to the liver parenchyma was convincingly argued to explain the striking non-bile-acid-dependent choleretic effect of unconjugated bile acids. A highlight of this presentation was the information that the manatee produced an unusual pattern ofbile acids, perhaps not surprising in that this sea-cow lives on an exclusive diet of waterlilies and its own faeces. Illustrations were offered to explain the concept that conjugation ofbile acids largely inhibits passivejejunal absorption, while promoting ileal conservation by the active transport mechanism.
A section of the meeting was devoted to the physiology of bile secretion. Professor S Erlinger beautifully illustrated the mechanism of passage of bile acids through the parenchymal cell in association with transport protein, and entry into the Golgi apparatus prior to secretion at the canuliculus. Dr R Coleman explained that at the canuliculus the bile acids were joined by phospholipid and cholesterol which had been secreted across the cell membrane as vesicles.
Our concepts ofbiliary lipid chemistry have become very much more sophisticated over the years. The simple display of lipid cholesterol and bile acids on triangular co-ordinates to express true cholesterol solubility in mixed micelles ofbile acid and phospholipids has always been an over-simplification, in that the water component of the system is crucial and the conventional diagram offered postulates 90% water content. True cholesterol solubility is influenced by different content of solids and in addition some cholesterol is carried either in the metastable liquid crystals (partially disorderly arrays of cholesterol and phospholipids). A more recent development is the concept of vesicular secretion of phospholipid and cholesterol in bile. These vesicles dynamically associate with bile acids in bile to form micellar aggregates, and clearly the time after initial secretion of bile is crucial in defining its chemical constitution. The meeting was privileged to have Dr M Carey, the world expert in this field, to guide it through this important but biochemically labile area.
A discussion of the pathophysiology of bile and the mechanism of gallstone formation followed. The crucial biochemical defect remains controversial, but may be very largely explained by the over-activity of hepatic HMG co-enzyme A reductase, which is ratelimiting for cholesterol synthesis. Whether there is a true pathogenetic role for reduced activity of cholesterol 7 alpha-hydroxylase and hence effective bile acid synthesis seems -doubtful currently.
Dr K Einar8son discussed various conditions known to be associated with cholesterol gallstone formation which are linked to enhanced cholesterol content of bile and increased cholesterol secretion, such as advancing age, obesity and treatment with fibric acid derivatives.
Physiochemical defects in bile were discussed at length by Dr T Holzbach. Modern concepts of nucleation timethe length of time which cholesterol crystals take to appear in bilewere described at length. Concentration has a role to play here: nucleation is delayed in biles more dilute than 10 g of solids/dl, but this may not be relevant to gallbladder bile. Part ofthe process of nucleation appears to relate to the aggregation of lipid vesicles, and this seems to be promoted by glycoprotein and inhibited by the lipid apoproteins in bile.
Recent studies of gallbladder motor function were discussed by Drs A Lanzini and I Forgacs. The concept of the gallbladder acting as a passive receptacle for bile, which it then squirts out in vigorous contractions when a meal is eaten, is known to be erroneous; and there is continuous filling and emptying even duringfasting. There are abnormalities of gallbladder contraction in gallstone patients, but whether these are the cause or a consequence is not yet clear. However, they must have relevance for the 0141-0768/88/ 050301-02/$02.00/0 © 1988 The Royal Society of Medicine
